919-206-7900
Polarean Imaging plc.'s technology is for research use only

Corporate News

Licencing Agreement with Duke University

13 November 2018

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, provides shareholders with the following update on Company progress:

Patent Licence / New Market Opportunity in Pulmonary Vascular Disease

The Company announces that it has entered into a licencing agreement with Duke University for patents related to an entirely new use for hyperpolarised gas imaging in the field of pulmonary vascular disease ('PVD'). This opens the potential for Polarean to address an additional unmet medical need in diagnosis and monitoring of cardiopulmonary conditions.

Pulmonary vascular disease (PVD) is a group of disorders that cause high blood pressure in the lungs (pulmonary hypertension). Prevalence is significant in the western world, and hundreds of thousands of patients suffer from the disease in the US alone (source: American Thoracic Society link). Specifically, pulmonary arterial hypertension ('PAH') is difficult to diagnose and requires invasive and expensive heart catheterisation to diagnose. New drugs are available to address PAH, but these drugs are driving up the average annual cost of caring for some of these patients to over US $100,000. As such, frequent monitoring of the effectiveness of these new therapies is essential.

Duke University has recently patented a method of using hyperpolarised gas MRI in a novel, non-invasive manner to quantify pulmonary vascular pressure, potentially eliminating the need for the costly and invasive catheterisation required to confirm PVD and monitor its progression.

The licencing agreement with Duke University grants Polarean exclusive rights to the technology, and the Company will work with Duke to drive this new technology towards clinical use and regulatory approval. This license further strengthens the previous licensing of Duke's 3D gas exchange imaging technology to provide a complete diagnostic suite that addresses a critical unmet need in the care of patients with PVD.

Richard Hullihen, CEO of Polarean, said: "We are delighted to expand our collaboration with Duke University and are especially excited to be co-developing this novel use for hyperpolarised MRI. With this extension of hyperpolarised xenon technology, we are expanding the usefulness of our core technology to fully address diseases of the airways, lung parenchyma, and now the pulmonary vasculature."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman  
   
Northland Capital Partners Limited Tel: +44 (0)20 3861 6625
David Hignell / Gerry Beaney / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
 
   
MC Services (European IR) Tel: +49 (0)89 210 2280
Raimund Gabriel  
   
The Life Sciences Division (Financial Adviser)  
Navid Malik, Director Mob: 07957 224 730
Alia Minhas, CEO Mob: 07590 696 057
   
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy
Helen Cresswell
Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001
Mob: +44 (0)7841 917 679

 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US $150 billion.

The Group is currently undertaking Phase III Non-Inferiority Clinical Trials for 129Xe at Duke University and University of Virginia.

 

« back to Corporate News